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And what we have been introduced to by
some of the data shown by Dr. Hull is that LMWH
is going to take over. It’s probably going to be the
best method of treatment, one injection a day,
send the patient home early. There is less bleed-
ing, less recurrence, decreased mortality.
So we have entered into a new era, and there
is no comparison of any form between thrombec-
tomy, thrombolysis, and this modern, effective
method of LMWH therapy.
And I come to the final question: If we are
going to set up studies now so that in ten years’
time there is some good evidence so we can make
good recommendations, what sort of studies
should we be setting up to compare thrombolysis
versus adequate heparin therapy, thrombectomy
versus adequate heparin therapy, or a combina-
tion ? What’s wrong with doing a thrombectomy
and carrying on with proper heparin therapy?
I’d like to start with you, Russell, and then go
to other members of the panel.
DR. HULL: In essence, you need different
types of databases. You need clinical outcome tri-
als that state whether the patient benefited or
not, and that’s straightforward.
You then need explanatory data to try and
provide an explanation for the pathophysiology
as it links to clinical outcome, and the analogy
would be the pharmacology data with heparin
and clinical outcome because both are crucial.
Then the issue is what type of pathophysio-
logical end points do you wish to use? And my col-
leagues will answer those. There are a number.
DR. RUTHERFORD: Well, in terms of this par-
ticular issue, I think you’d have to have selected
patients. I mean, you’d have to have inclusions
and exclusions, obviously, and end up with a
group of patients who might benefit.
You wouldn’t apply this across the board to
all DVT, obviously. You might end up with either
three arms of therapy, or you might combine
thrombolysis and thrombectomy in an interven-
tional arm, using one or the other, depending on
an algorithm like the one I showed, versus op-
tional heparin usage.
And then finally, the outcome analysis will be
crucial, and we’ve got to include a cost compari-
son in all of this, and include the complications to
be able to do a real risk-benefit analysis at the end.
DR. NICOLAIDES: And what end points are
you going to use?
DR. RUTHERFORD: My feeling is that we
may have to use a combined end point of change
in clinical class and some hemodynamic evidence
of improvement.
Then you’d have a number of secondary end
points. Quality of life will be important, and
there’s one now being developed and tested that
combines standard quality-of-life measures with
specific venous questions, which Tony Comerota is
working on.
DR. NICOLAIDES: This is a key question. And
I’d like all of you to think about it, and we’ll come
back to it tomorrow and on Sunday. What end
points are we going to be using in future studies.
Well, thank you.
The Case for Aggressive Treatment
of Pulmonary Embolism
Lazar J. Greenfield, MD
University of Michigan Hospitals. Ann Arbor, Michigan, USA
Effective management of pulmonary throm-
boembolism requires first and foremost that the
diagnosis be confirmed. Under most circum-
stances of &dquo;classical&dquo; signs and symptoms, when
pulmonary angiography is obtained it will prove
to be negative (71% in our experience). This com-
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pletely redirects the patient’s management, often
with recognition of unsuspected sepsis. When the
angiogram is positive, simultaneous measurement
of the pulmonary arterial pressure while the
catheter is in the pulmonary artery allows classifi-
cation of the patients based on the hemodynamic
effects of the event in the patient (Table I).
Minor degrees of pulmonary thromboem-
bolism are characterized by symptoms of cough,
dyspnea, and anxiety with signs of tachypnea and
tachycardia. Since these patients have not sus-
tained a systemic hemodynamic effect, they are
candidates for screening lung scan since a nega-
tive scan essentially excludes the diagnosis. A pos-
itive scan is subject to the criteria developed in
the PIOPED study with reliance only upon a high
probability reading. In the face of an intermediate
probability reading, the diagnosis can be rein-
forced by duplex noninvasive venous examina-
tion, justifying a course of anticoagulation. Major
pulmonary embolism can be defined as that de-
gree of acute pulmonary vascular obstruction suf-
ficient to produce systemic hypotension, which is
usually transient and responds to resuscitation
(Table I) . When the hypotension is sustained and
requires vasopressor support to maintain systemic
blood pressure, the patient is considered to have
massive pulmonary embolism and becomes a can-
didate for pulmonary embolectomy. If the patient
has chronic recurrent thromboembolism, the pre-
sentation may be similar, but there are signs of
chronic pulmonary hypertension and cor pul-
monale.
Patients who are in shock are managed by ad-
ministration of heparin (100-150,u/kg) and place-
ment of radial and pulmonary arterial catheters.
After angiographic confirmation of the diagnosis
with the patient remaining on the fluoroscopy
table, a steerable cup-catheter* is inserted under
local anesthesia through either the right femoral
or internal jugular vein. The technique of catheter
embolectomy has been described and modified re-
cently only by more frequent use of the jugular
rather than the femoral vein. The procedure is
completed by insertion of a vena caval filter.
Transvenous catheter embolectomy is a safe,
effective, and expeditious modality in patients with
acute embolism who do not require continuous
closed-chest cardiac massage. Forty-seven patients
have been treated with this technique. Emboli
were extracted successfully in 37 of them (79%)
with survival in 33 (70%). In four of the last five
cases, the indications were broadened to include
patients who had become respirator dependent,
and all had relief of pulmonary hypertension with
rapid ability to wean from the respirator.
If catheter embolectomy fails, or if closed-
chest massage is required, open embolectomy
should be performed on cardiopulmonary bypass.
In our most recent experience, five of eight pa-
tients who underwent open embolectomy survived
(63%). Since catheter pulmonary embolectomy
can be performed under local anesthesia in the ra-
diology suite as soon as the diagnosis is confirmed,
it represents an appropriate initial effort to treat
major or massive pulmonary thromboembolism.
Table I
Stratification of Pulmonary Thromboembolism
305
Reading List
1. Langham MR Jr, Greenfield LJ: Transvenous catheter
embolectomy for life-threatening pulmonary throm-
boembolism. Inf in Surg 5:694, 1986.
2. Greenfield LJ: Invited editorial comment. In: Moore
JH Jr, Koolpe HA, Carabasi RA, Yang SL, Jarrell BE:
Transvenous catheter pulmonary embolectomy. Arch
Surg 120:1375, 1985.
3. Stewart JR, Greenfield LJ: Transvenous vena caval
filtration and pulmonary embolectomy. Surg Clin
North Am 62:411-430, 1982.
4. PIOPED Investigators: Value of the ventilation/per-
fusion scan in acute pulmonary embolism. JAMA
263:2753, 1990.
* MediTech, Inc., Watertown, Pa
The Case Against Aggressive Treatment in PE
Thomas M. Hyers, MD
Saint Louis University School of Medicine, St. Louis, Missouri, USA
The natural history of pulmonary embolism
indicates that in most cases conservative treat-
ment with properly administered anticoagulants
is sufficient. These studies have shown that pul-
monary emboli occur in clusters in most patients
before the process is diagnosed. When proper
therapy with heparin and warfarin are initiated,
the short-term outcome is usually good. Although
natural history studies show that some 25% of pa-
tients with pulmonary embolism die in the year
following diagnosis, most of these individuals die
of comorbidity and not directly from venous
thromboembolism. Only 10% of deaths in the
year following pulmonary embolism occur from
recurrent pulmonary embolism. The other 90%
of deaths are attributable to preexisting disease
which is usually cardiopulmonary disease or
cancer.
This thesis is predicated on the proper use of
heparin and warfarin. Heparin must be given in
sufficient quantity, monitored, and dose-adjusted
to halt the progression of thrombus so as to allow
the body’s natural processes to resolve the throm-
bus. This goal has always been problematic be-
cause of the unpredictable kinetics of heparin.
Warfarin also must be given in the proper amount
to achieve an INR in the range of 2-3 long term to
allow the resolution of the thrombophilic process.
In some cases patients with ongoing predisposi-
tions to pulmonary embolism such as malignancy
or inherited thrombophilic conditions will require
anticoagulation with warfarin beyond the usually
prescribed three to six months.
The advent of low-molecular-weight heparins
opens a new era in the treatment of venous
thrombosis. Low-molecular-weight heparins can
be given on a weight-based dosing regimen
without subsequent monitoring or dose adjust-
ment. In comparison to standard heparin,
LMWH is more likely to arrest thrombus growth
and reduces the rates of bleeding and thrombo-
cytopenia. This allows for more effective thera-
py with a stronger likelihood of completely ar-
resting the thrombotic process. In addition,
LMWHs offer the opportunity for outpatient
treatment or early hospital discharge in selected
stable patients. LMWHs should enhance our
ability to treat most patients with pulmonary
embolism without the use of more invasive
therapy.
The few patients who die immediately of
pulmonary embolism usually do so before any
medical or surgical therapy can be instituted.
Patients who survive for at least one hour with
pulmonary embolism are very likely to survive
for the long term if proper anticoagulation is
promptly instituted. In this setting, a few se-
lected patients can benefit from the use of
thrombolytic therapy. Although there is no con-
trolled clinical evidence that thrombolytic ther-
apy reduces mortality in acute massive pul-
monary embolism, clinical experience has shown
it to be effective in the selected patient with
life-threatening pulmonary embolism who is
hemodynamically unstable. Given this approach
to therapy, surgical intervention for acute pul-
monary embolism should be reserved for the
very few patients who are hemodynamically
unstable and not candidates for thrombolytic
therapy.
